ceftaroline
Selected indexed studies
- Ceftaroline. (Rev Esp Quimioter, 2021) [PMID:34598420]
- Ceftaroline in severe community-acquired pneumonia. (Rev Esp Quimioter, 2022) [PMID:35488821]
- Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia. (Eur Respir Rev, 2023) [PMID:37852658]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ceftaroline. (2021) pubmed
- Ceftaroline in severe community-acquired pneumonia. (2022) pubmed
- Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia. (2023) pubmed
- Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance. (2022) pubmed
- Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study. (2025) pubmed
- Ceftaroline fosamil: A super-cephalosporin? (2015) pubmed
- Ceftaroline: a comprehensive update. (2011) pubmed
- Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. (2017) pubmed
- Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. (2019) pubmed
- Ceftaroline: a new broad-spectrum cephalosporin. (2011) pubmed